FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2530301420> ?p ?o ?g. }

• W2530301420 abstract "Abstract Introduction Platelets may comprise an ideal vehicle for delivering FVIII in hemophilia A (HemA) as FVIII stored in platelet α-granules is protected from neutralization by inhibitory antibodies and, during bleeding, activated platelets locally excrete their contents to promote clot formation. In order to avoid specific challenges posed by ex vivo gene delivery including, in particular, the requirement to pre-condition the subject, we evaluated intraosseous (IO) infusion of self-inactivating lentiviral vectors (LV) for in situ gene transfer into bone marrow cells. In previous studies, we confirmed that hematopoietic stem cells (HSCs) can be efficiently transduced to express GFP after IO administration of LV driven by a MND promoter (M-GFP-LV). Methods In the current study, we aimed at limiting transgene expression to the megakaryocyte lineages using IO delivery of 20 µL LV containing either GFP (G-GFP-LV) or a B-domain variant human FVIII (G-F8-LV) gene under the control of megakaryocyte strictly specific promoter glycoprotein 1bα (Gp1bα). Results In M-GFP-LV treated control mice, GFP was detected in 6.4% of HSCs, 3.4% of B220+, and 9.0% of CD11c+ bone marrow cells on day 29. In contrast, in G-GFP-LV (6.0E+08 TU/mL) treated mice, GFP was undetectable in bone marrow HSCs, B220+, CD11c+ or CD11b+ cells. GFP expression level in platelets of G-GFP-LV treated mice was ten folds of that in M-GFP-LV treated mice (0.1% vs 0.01%). It indicated that in platelets, the activity of Gp1bα was stronger than that of MND. More importantly, GFP expression levels were stable over 100 days, suggesting that platelets containing the transgene products did not elicit transgene-specific immune responses. Next, we treated HemA mice with G-F8-LV (6.0 E+07 TU/mL). There was no detectable hFVIII expression in bone marrow HSCs on day 8 or in blood cells (CD3ε+, B220+, CD11c+ or CD11b+) on day 35. However, up to 3% platelets express hFVIII on day 91. These results suggested that HSCs in HemA mice were successfully transduced by G-F8-LV after IO infusion, and in the long term, FVIII was synthesized in megakaryocytes and stored in platelet α-granules. In treated mice, the average percentage of platelets expressing hFVIII was stable at 1-2% from day 27 to day 160. The average FVIII antigen level in platelets on day 112 was 1 mU per 1 × 108 platelets, which was comparable with platelet FVIII in transgenic and ex vivo gene therapy treated mice. We also evaluated LV-treated HemA animals for phenotypic correction of bleeding diathesis by tail clip assay. The blood loss was 41% (n=7), 48% (n=5) and 33% (n=5) compared with control HemA (normalized to 100%), mock treated HemA (∼100%), and wild-type (2.5%) mice on days 35, 118 and 160, respectively. Additionally, there was neither detectable FVIII activity nor anti-FVIII antibodies in blood on day 160, which indicated that there was insignificant leaky expression of FVIII in other cells. Finally, we also infused G-F8-LV into HemA inhibitor mice. Inhibitors were induced by repeated injection of 3U recombinant hFVIII. The average antibody level was 80 Bethesda Unit before IO infusion of the vectors. In G-F8-LV treated mice, the average hFVIII antigen level on day 27 was 0.74 mU per 1 x 108 platelets (n=5). Bleeding assay was performed on day 160. The blood loss of treated mice was significantly reduced compared with untreated HemA mice, indicating that IO infusion of G-F8-LV can overcome anti-FVIII antibodies and correct hemophilia phenotype. Conclusion We have successfully transduced HSCs in situ by a single infusion of LVs into bone marrow to correct hemophilia A. Gp1bα promoter in lentiviral vectors can specifically direct the transgene expression in mouse platelets. Following IO infusion of G-F8-LV, FVIII stored in platelets can persistently and partially correct the HemA phenotype for at least five months (experimental duration) in mice with and without pre-existing inhibitors. Overall, direct transduction of bone marrow cells targeting platelet-specific FVIII expression may provide an effective therapy to treat severe hemophilia A patients with high-titer inhibitors. Disclosures: No relevant conflicts of interest to declare." @default.
• W2530301420 created "2016-10-21" @default.
• W2530301420 creator A5004382555 @default.
• W2530301420 creator A5022447244 @default.
• W2530301420 creator A5027470095 @default.
• W2530301420 creator A5064642542 @default.
• W2530301420 creator A5089810947 @default.
• W2530301420 date "2013-11-15" @default.
• W2530301420 modified "2023-09-28" @default.
• W2530301420 title "Murine Hemophilia A With Or Without Pre-Existing Anti-Factor VIII Inhibitors Is Partially Corrected By Factor VIII Stored In Platelets After Intraosseous Infusion Of Lentiviral Vectors Into Bone Marrow Without Preconditioning" @default.
• W2530301420 doi "https://doi.org/10.1182/blood.v122.21.719.719" @default.
• W2530301420 hasPublicationYear "2013" @default.
• W2530301420 type Work @default.
• W2530301420 sameAs 2530301420 @default.
• W2530301420 citedByCount "0" @default.
• W2530301420 crossrefType "journal-article" @default.
• W2530301420 hasAuthorship W2530301420A5004382555 @default.
• W2530301420 hasAuthorship W2530301420A5022447244 @default.
• W2530301420 hasAuthorship W2530301420A5027470095 @default.
• W2530301420 hasAuthorship W2530301420A5064642542 @default.
• W2530301420 hasAuthorship W2530301420A5089810947 @default.
• W2530301420 hasConcept C10205521 @default.
• W2530301420 hasConcept C104317684 @default.
• W2530301420 hasConcept C109159458 @default.
• W2530301420 hasConcept C111599444 @default.
• W2530301420 hasConcept C142613039 @default.
• W2530301420 hasConcept C153911025 @default.
• W2530301420 hasConcept C16685009 @default.
• W2530301420 hasConcept C185592680 @default.
• W2530301420 hasConcept C203014093 @default.
• W2530301420 hasConcept C2779705218 @default.
• W2530301420 hasConcept C2780007613 @default.
• W2530301420 hasConcept C28328180 @default.
• W2530301420 hasConcept C32470452 @default.
• W2530301420 hasConcept C40767141 @default.
• W2530301420 hasConcept C55493867 @default.
• W2530301420 hasConcept C71924100 @default.
• W2530301420 hasConcept C86803240 @default.
• W2530301420 hasConcept C89560881 @default.
• W2530301420 hasConcept C95444343 @default.
• W2530301420 hasConceptScore W2530301420C10205521 @default.
• W2530301420 hasConceptScore W2530301420C104317684 @default.
• W2530301420 hasConceptScore W2530301420C109159458 @default.
• W2530301420 hasConceptScore W2530301420C111599444 @default.
• W2530301420 hasConceptScore W2530301420C142613039 @default.
• W2530301420 hasConceptScore W2530301420C153911025 @default.
• W2530301420 hasConceptScore W2530301420C16685009 @default.
• W2530301420 hasConceptScore W2530301420C185592680 @default.
• W2530301420 hasConceptScore W2530301420C203014093 @default.
• W2530301420 hasConceptScore W2530301420C2779705218 @default.
• W2530301420 hasConceptScore W2530301420C2780007613 @default.
• W2530301420 hasConceptScore W2530301420C28328180 @default.
• W2530301420 hasConceptScore W2530301420C32470452 @default.
• W2530301420 hasConceptScore W2530301420C40767141 @default.
• W2530301420 hasConceptScore W2530301420C55493867 @default.
• W2530301420 hasConceptScore W2530301420C71924100 @default.
• W2530301420 hasConceptScore W2530301420C86803240 @default.
• W2530301420 hasConceptScore W2530301420C89560881 @default.
• W2530301420 hasConceptScore W2530301420C95444343 @default.
• W2530301420 hasLocation W25303014201 @default.
• W2530301420 hasOpenAccess W2530301420 @default.
• W2530301420 hasPrimaryLocation W25303014201 @default.
• W2530301420 hasRelatedWork W124424966 @default.
• W2530301420 hasRelatedWork W1561129559 @default.
• W2530301420 hasRelatedWork W1964178121 @default.
• W2530301420 hasRelatedWork W2243340658 @default.
• W2530301420 hasRelatedWork W2374699275 @default.
• W2530301420 hasRelatedWork W2466569762 @default.
• W2530301420 hasRelatedWork W2512552023 @default.
• W2530301420 hasRelatedWork W2529859205 @default.
• W2530301420 hasRelatedWork W2551400504 @default.
• W2530301420 hasRelatedWork W2553136045 @default.
• W2530301420 hasRelatedWork W2554737946 @default.
• W2530301420 hasRelatedWork W2554744115 @default.
• W2530301420 hasRelatedWork W2555105507 @default.
• W2530301420 hasRelatedWork W2562021753 @default.
• W2530301420 hasRelatedWork W2574855891 @default.
• W2530301420 hasRelatedWork W2586128448 @default.
• W2530301420 hasRelatedWork W2616792233 @default.
• W2530301420 hasRelatedWork W2751738405 @default.
• W2530301420 hasRelatedWork W2789947753 @default.
• W2530301420 hasRelatedWork W2993518707 @default.
• W2530301420 isParatext "false" @default.
• W2530301420 isRetracted "false" @default.
• W2530301420 magId "2530301420" @default.
• W2530301420 workType "article" @default.